ReviewMolecular diagnosis & therapy2018
Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.
Review in Molecular diagnosis & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- How Successful is Switching from Bevacizumab or Ranibizumab to Aflibercept in Age-Related Macular Degeneration? A Systematic Overview.Advances in therapy · 2019Pooled it
- Artificial intelligence-driven diagnosis for age-related macular degeneration bridging pathology and engineering: a survey.International ophthalmology · 2025Review
- Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2023Observational
- Associations of VEGF Polymorphisms With Retinopathy of Prematurity.Investigative ophthalmology & visual science · 2023Article
- Aortic stiffness and systemic inflammation changes predict clinical response to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration.Journal of human hypertension · 2023Article
- The Need for Artificial Intelligence Based Risk Factor Analysis for Age-Related Macular Degeneration: A Review.Diagnostics (Basel, Switzerland) · 2022Review
- Polygenic Risk Score Impact on Susceptibility to Age-Related Macular Degeneration in Polish Patients.Journal of clinical medicine · 2022Article
- Effects ofInternational journal of molecular sciences · 2022Article
- WAMD: From Pathophysiology to Therapeutic Treatments.Biomedicines · 2022Article
- Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration.Biomedicines · 2022Article
- Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment.Journal of personalized medicine · 2021Article
- A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Biological surface properties in extracellular vesicles and their effect on cargo proteins.Scientific reports · 2019Article
- Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration.BMJ open ophthalmology · 2019Article
- Haplotypes ofDisease markers · 2019Article
- Metabolomics and Age-Related Macular Degeneration.Metabolites · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Precision medicine aims to improve patient care by adjusting medication to each patient's individual needs. Age-related macular degeneration (AMD) is a heterogeneous eye disease in which several pathways are involved, and the risk factors driving the disease differ per patient. As a consequence, precision medicine holds promise for improved management of this disease, which is nowadays a main cause of vision loss in the elderly. In this review, we provide an overview of the studies that have evaluated the use of molecular biomarkers to predict response to treatment in AMD. We predominantly focus on genetic biomarkers, but also include studies that examined circulating or eye fluid biomarkers in treatment response. This involves studies on treatment response to dietary supplements, response to anti-vascular endothelial growth factor, and response to complement inhibitors. In addition, we highlight promising new therapies that have been or are currently being tested in clinical trials and discuss the molecular studies that can help identify the most suitable patients for these upcoming therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.